Alcohol and Alcoholism Advance Access originally published online on July 25, 2005
Alcohol and Alcoholism 2005 40(6):545-548; doi:10.1093/alcalc/agh187
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AN OPEN RANDOMIZED STUDY COMPARING DISULFIRAM AND ACAMPROSATE IN THE TREATMENT OF ALCOHOL DEPENDENCE
Get Well Clinic And Nursing Home, 33rd Road, Off Linking Road, Bandra, Mumbai 400050, Maharashtra State, India
* Author to whom correspondence should be addressed: Tel.: +91 22 26460785; E-mail: avinashdes999{at}yahoo.co.uk
(Received 11 March 2005; first review notified 6 June 2005; in final revised form 21 June 2005; accepted 2 July 2005)
Aims: To compare the efficacy of acamprosate (ACP) and disulfiram (DSF) for preventing alcoholic relapse in routine clinical practice. Methods: One hundred alcoholic men with family members who would encourage medication compliance and accompany them for follow-up were randomly allocated to 8 months of treatment with DSF or ACP. Weekly group psychotherapy was also available. The psychiatrist, patient, and family member were aware of the treatment prescribed. Alcohol consumption, craving, and adverse events were recorded weekly for 3 months and then fortnightly. Serum gamma glutamyl transferase was measured at the start and the end of the study. Results: At the end of the trial, 93 patients were still in contact. Relapse (the consumption of >5 drinks/40 g of alcohol) occurred at a mean of 123 days with DSF compared to 71 days with ACP (P = 0.0001). Eighty-eight per cent of patients on DSF remained abstinent compared to 46% with ACP (P = 0.0002). However, patients allocated to ACP had lower craving than those on DSF (P = 0.002). Conclusion: DSF is superior to ACP for preventing relapse in alcohol-dependent men with good family support. Further comparisons between these two drugs in different treatment settings and populations are warranted.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Mutschler, M. Buhler, M. Grosshans, A. Diehl, K. Mann, and F. Kiefer Disulfiram, an Option for the Treatment of Pathological Gambling? Alcohol Alcohol., March 1, 2010; 45(2): 214 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mutschler, M. Grosshans, A. Koopmann, D. Hermann, A. Diehl, K. Mann, and F. Kiefer Supervised Disulfiram in Relapse Prevention in Alcohol-Dependent Patients Suffering From Comorbid Borderline Personality Disorder--A Case Series Alcohol Alcohol., March 1, 2010; 45(2): 146 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Neto, R. Lambaz, P. Aguiar, and J. Chick Effectiveness of Sequential Combined Treatment in Comparison with Treatment as Usual in Preventing Relapse in Alcohol Dependence Alcohol Alcohol., November 1, 2008; 43(6): 661 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Laaksonen, A. Koski-Jannes, M. Salaspuro, H. Ahtinen, and H. Alho A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence Alcohol Alcohol., January 1, 2008; 43(1): 53 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Neto, R. Lambaz, and J. E. Tavares Compliance with aftercare treatment, including disulfiram, and effect on outcome in alcohol-dependent patients Alcohol Alcohol., November 1, 2007; 42(6): 604 - 609. [Abstract] [Full Text] [PDF]
|
|